Oncolytics Biotech (ONCY) Total Liabilities (2009 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Total Liabilities of $11.4 million for Q4 2025, up 11.93% year-over-year from $10.2 million in Q4 2024, and up 4.82% quarter-over-quarter from $10.9 million in Q3 2025.
Oncolytics Biotech (ONCY) Total Liabilities (2009 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Total Liabilities for 17 consecutive years, with $11.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Liabilities rose 11.93% year-over-year to $11.4 million; the TTM figure through Dec 2025 stood at $11.4 million (up 11.93% YoY), while the FY2025 annual figure was $11.4 million, up 12.43% from the prior year.
- Total Liabilities advanced to $11.4 million in Q4 2025 per ONCY's latest filing, from $10.9 million in the prior quarter.
- Across five years, Total Liabilities topped out at $12.7 million in Q3 2023 and bottomed at $7.1 million in Q1 2023.
- Historically, Total Liabilities has averaged $8.9 million across 5 years, with a median of $8.2 million in 2022.
- Annual changes were most pronounced in 2021 — Total Liabilities tumbled 32.43% — and 2023, when it surged 57.23%.
- Oncolytics Biotech's Total Liabilities stood at $7.8 million in 2021, then climbed by 2.84% to $8.0 million in 2022, then increased by 3.62% to $8.3 million in 2023, then gained by 22.97% to $10.2 million in 2024, then gained by 11.93% to $11.4 million in 2025.
- Business Quant data shows ONCY's Total Liabilities at $11.4 million in Q4 2025, $10.9 million in Q3 2025, and $10.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Oncolytics Biotech | 96.23 Mn | 96.23 Mn | - | 13.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.84 Mn |
| Dec 31, 2025 | 11.38 Mn |
| Sep 30, 2025 | 10.86 Mn |
| Jun 30, 2025 | 10.02 Mn |
| Mar 31, 2025 | 9.20 Mn |
| Dec 31, 2024 | 10.17 Mn |
| Sep 30, 2024 | 11.15 Mn |
| Jun 30, 2024 | 10.06 Mn |
| Mar 31, 2024 | 8.74 Mn |
| Dec 31, 2023 | 8.27 Mn |
| Sep 30, 2023 | 12.73 Mn |
| Jun 30, 2023 | 7.24 Mn |
| Mar 31, 2023 | 7.08 Mn |
| Dec 31, 2022 | 7.98 Mn |
| Sep 30, 2022 | 8.10 Mn |
| Jun 30, 2022 | 7.42 Mn |
| Mar 31, 2022 | 7.45 Mn |
| Dec 31, 2021 | 7.76 Mn |
| Sep 30, 2021 | 7.85 Mn |
| Jun 30, 2021 | 7.99 Mn |